PMID- 33506275
OWN - NLM
STAT- MEDLINE
DCOM- 20210518
LR  - 20211204
IS  - 1573-4978 (Electronic)
IS  - 0301-4851 (Linking)
VI  - 48
IP  - 2
DP  - 2021 Feb
TI  - Differential expression of ABCB1, ABCG2, and KLF4 as putative indicators for 
      paclitaxel resistance in human epithelial type 2 cells.
PG  - 1393-1400
LID - 10.1007/s11033-021-06167-6 [doi]
AB  - Laryngeal squamous cell carcinoma (LSCC) is the second most common malignancy of 
      the head and neck region in the USA with a declining 5-year survival rate. 
      Paclitaxel resistance of tumors including LSCC still stands as a vital cause for 
      poor clinical outcome in patients. In the current study, our aim was to explore 
      the expressions of ATP-binding cassette transporters and stemness associated 
      genes in human epithelial type 2 (Hep-2) cells with paclitaxel resistance. 
      Resistant cells were developed via treatment with increasing doses of paclitaxel 
      to acquire four sub-lines resistant to one-, two-, four-, and eightfold 
      concentrations of paclitaxel (1x, 2x, 4x, 8x). Then, we profiled the expressions 
      of ten selected ABC transporters (ABCA5, ABCB1, ABCB6, ABCC1, ABCC2, ABCC3, 
      ABCC5, ABCC10, ABCF2, and ABCG2) and four stem cell markers (SOX2, OCT4, KLF, and 
      CXCR4) using quantitative real time polymerase chain reaction in paclitaxel 
      resistant cells to look for a link between these markers and chemoresistance. We 
      demonstrated that ABCB1 and ABCG2 expressions gradually elevated and reached a 
      maximum level in Taxol 8x cells. Considering stem cell markers, KLF4 expression 
      elevated significantly, as soon as parental cells acquired resistance to the 
      lowest dose of paclitaxel and its expression elevated stepwise. Expression levels 
      of other tested ATP-binding cassette transporters and stem cell markers also 
      elevated, although at different steps of paclitaxel resistance acquisition. Our 
      findings suggest that higher expressions of ABCB1, ABCG2, and KLF4 might be 
      considered as putative indicators for paclitaxel resistance in LSCC patients.
FAU - Duz, Mehmet Bugrahan
AU  - Duz MB
AD  - Department of Medical Genetics, Haseki Training and Research Hospital, Istanbul, 
      Turkey.
FAU - Karatas, Omer Faruk
AU  - Karatas OF
AUID- ORCID: 0000-0002-0379-2088
AD  - Department of Molecular Biology and Genetics, Erzurum Technical University, Omer 
      Nasuhi Bilmen Mah. Havaalani Yolu Cad. No: 53 Yakutiye, Erzurum, Turkey. 
      faruk.karatas@erzurum.edu.tr.
AD  - High Technology Application and Research Center, Erzurum Technical University, 
      Erzurum, Turkey. faruk.karatas@erzurum.edu.tr.
LA  - eng
PT  - Journal Article
DEP - 20210128
PL  - Netherlands
TA  - Mol Biol Rep
JT  - Molecular biology reports
JID - 0403234
RN  - 0 (ABCB1 protein, human)
RN  - 0 (ABCC2 protein, human)
RN  - 0 (ABCG2 protein, human)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily B)
RN  - 0 (ATP Binding Cassette Transporter, Subfamily G, Member 2)
RN  - 0 (Antineoplastic Agents)
RN  - 0 (KLF4 protein, human)
RN  - 0 (Kruppel-Like Factor 4)
RN  - 0 (Kruppel-Like Transcription Factors)
RN  - 0 (Multidrug Resistance-Associated Protein 2)
RN  - 0 (Neoplasm Proteins)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - ATP Binding Cassette Transporter, Subfamily B/genetics
MH  - ATP Binding Cassette Transporter, Subfamily G, Member 2/*genetics
MH  - Antineoplastic Agents/pharmacology
MH  - Cell Line, Tumor
MH  - Drug Resistance, Multiple/genetics
MH  - Drug Resistance, Neoplasm/genetics
MH  - Epithelial Cells/drug effects
MH  - Gene Expression Regulation, Neoplastic/drug effects
MH  - Humans
MH  - Kruppel-Like Factor 4
MH  - Kruppel-Like Transcription Factors/*genetics
MH  - Multidrug Resistance-Associated Protein 2
MH  - Neoplasm Proteins/*genetics
MH  - Paclitaxel/adverse effects/pharmacology
MH  - Squamous Cell Carcinoma of Head and Neck/*drug therapy/genetics/pathology
OTO - NOTNLM
OT  - ABC transporters
OT  - Hep-2 cells
OT  - Laryngeal squamous cell carcinoma
OT  - Paclitaxel
OT  - Stem cell markers
EDAT- 2021/01/29 06:00
MHDA- 2021/05/19 06:00
CRDT- 2021/01/28 05:45
PHST- 2020/10/23 00:00 [received]
PHST- 2021/01/15 00:00 [accepted]
PHST- 2021/01/29 06:00 [pubmed]
PHST- 2021/05/19 06:00 [medline]
PHST- 2021/01/28 05:45 [entrez]
AID - 10.1007/s11033-021-06167-6 [pii]
AID - 10.1007/s11033-021-06167-6 [doi]
PST - ppublish
SO  - Mol Biol Rep. 2021 Feb;48(2):1393-1400. doi: 10.1007/s11033-021-06167-6. Epub 
      2021 Jan 28.